NDASUBCUTANEOUSINJECTABLE
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
9
Data completeness
4/8 — Partial
ALSUMA (sumatriptan succinate) by CooperSurgical is 5-ht 1b/1d receptors. First approved in 2010.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALSUMA is a subcutaneous injectable formulation of sumatriptan succinate, a 5-HT1B/1D receptor agonist approved in 2010. It is indicated for acute migraine treatment and works by constricting intracranial blood vessels and inhibiting pro-inflammatory neuropeptide release in the trigeminal system.
LOE Approaching11mo to LOE
Product is in late-stage lifecycle with approaching loss of exclusivity; team size likely contracted and focused on legacy management rather than growth initiatives.
Mechanism of Action
5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)
Started May 2008
30 enrolled
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
Started Dec 2006
169 enrolled
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Started Nov 2006
173 enrolled
Migraine Disorders
Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan
Started Jun 2006
75 enrolled
Migraine Disorders
Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions
Started Jul 2005
50 enrolled
Healthy
Worked on ALSUMA at CooperSurgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.